Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Gastrointestinal carcinoid tumor
Trial Type:  Treatment
Results 1-14 of 14 for your search:
Start Over
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CSOM230B2412, NCI-2017-01247, NCT01794793
Embolization Therapy with or without Chemotherapy in Controlling Liver Metastases in Patients with Neuroendocrine Tumor Metastases to the Liver That Cannot Be Removed by Surgery
Status: Active
Phase: Phase III
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: UPCC01215, NCI-2016-00610, NCT02724540
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Regorafenib in Treating Patients with Advanced or Metastatic Neuroendocrine Tumors
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-14-3, NCI-2014-01996, HS-14-00583, NCT02259725
Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 150040, 339636, P141605, NCT02315625
Pembrolizumab in Treating Patients with Previously Treated Metastatic High Grade Neuroendocrine Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GI-087, NCI-2016-01492, NCT02939651
Ph 1 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: POLARIS2013-001, NCI-2017-00851, NCT02102022
Ropidoxuridine in Treating Patients with Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9882, NCI-2015-00258, BRUOG 265, NCT02381561
Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9914, NCI-2015-02125, 17-C-0012, NCT02631733
68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 PET/CT in Diagnosing and Treating Patients with Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-161, NCI-2015-02110, NCT02609737
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients with Metastatic Gastrointestinal Tumors
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0152, NCI-2016-01058, NCT02757391
Iobenguane I-131 and Yttrium Y 90-Edotreotide in Treating Patients with Midgut Neuroendocrine Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201608857, NCI-2017-00636, NCT03044977
Start Over